Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Core Points - Mainz Biomed NV has regained compliance with Nasdaq's minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market as of January 23, 2025 [1] - The company had previously confirmed compliance with the minimum bid price requirement, and is now fully compliant with all Nasdaq continued listing requirements [1] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for early cancer detection, with its flagship product being ColoAlert, a non-invasive test for colorectal cancer [2] - ColoAlert is marketed in Europe and the UAE, and the company is conducting a pivotal FDA clinical study for US regulatory approval [2] - The product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples [2]